Predictors of acute ischemic cerebral lesions in immune-mediated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.

Date publication

juillet 2023

Journal

Journal of neurology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr OJEDA-URIBE Mario

Tous les auteurs :
Neuman L, Joseph A, Bouzid R, Lescroart M, Mariotte E, Ederhy S, Tuffet S, Baudel JL, Benhamou Y, Galicier L, Grangé S, Provôt F, Neel A, Pène F, Delmas Y, Presne C, Poullin P, Wynckel A, Perez P, Barbet C, Halimi JM, Chatelet V, Rebibou JM, Ojeda-Uribe M, Vigneau C, Mesnard L, Veyradier A, Azoulay E, Coppo P, Chabriat H,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37392208

Résumé

The immune form of thrombotic thrombocytopenic purpura (iTTP) and the hemolytic and uremic syndrome (HUS) are two major forms of thrombotic microangiopathy (TMA). Their treatment has been recently greatly improved. In this new era, both the prevalence and predictors of cerebral lesions occurring during the acute phase of these severe conditions remain poorly known.

Mots clés

Acute infarcts, Complications, Hemolytic uremic syndrome, MRI, Stroke, Thrombotic thrombocytopenic purpura

Référence

J Neurol. 2023 07 1;: